ONWARD Medical SA (Euronext: ONWD), a medical technology company creating innovative therapies aimed at restoring movement, independence and health to people with spinal cord injuries, will report first-half 2022 financial and operating results on Tuesday, September 27, 2022. Management will host a webcast to discuss operational and financial highlights, as well as provide an operations update on September 27, 2022, at 4:00 p.m. CET/10:00 a.m. EDT.
To join the webcast via Zoom, please use this link.
Participants can also attend by telephone:
+32 2 290 9360 (Belgium)
+49 69 3807 9884 (Germany)
+31 20 794 0854 (Netherlands)
+41 22 591 01 56 (Switzerland)
+44 203 481 5240 (UK)
+1 346 248 7799 (USA)
List of all available international numbers
Webinar ID: 840 0768 4745
A recording of the webcast will be available on the company’s website following the live event.
To learn more about ONWARD’s ARC Therapy and the company’s vision to restore movement, independence and health to people with spinal cord injury, please visit ONWD.com.
About ONWARD Medical
ONWARD is a medical technology company that creates innovative therapies to restore movement, independence and health to people with spinal cord injuries. ONWARD’s work is based on more than a decade of basic and preclinical scientific research conducted in the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered through implantable (ARC-IM) or external (ARC-EX) systems, is designed to provide targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injuries, improving their quality of life.
ONWARD has received three Breakthrough Device Designations from the FDA for the ARC-IM and ARC-EX systems. ARC-EX is an external, non-invasive platform composed of a portable stimulator and a wireless programmer. The first data was reported in September 2022 as part of the company’s first major study, titled Up-LIFT, which evaluates the ability of ARC-EX therapy to improve upper limb strength and function. The company is currently preparing marketing authorization applications in the United States and Europe. The ARC-IM consists of an implantable pulse generator and lead that are placed near the spinal cord. The company recently completed the first-in-human use of its ARC-IM neurostimulator in May 2022.
ONWARD’s head office is located on the High Tech Campus in Eindhoven, the Netherlands. A significant team is based in Lausanne, Switzerland, and its US presence is growing in Boston, Massachusetts, USA. For more company information, please visit ONWD.com. To access our 2022 financial calendar, please visit IR.ONWD.com.
Discharge of responibility
Certain statements, beliefs and opinions contained in this release are forward-looking and reflect the current expectations and projections of the company or, where applicable, the directors of the company regarding future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions, which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could have an adverse effect on the results and the financial effects of the plans and events described in this press release. A multitude of factors, including but not limited to changes in demand, competition and technology, could cause actual events, performance or results to differ materially from the , the developments initially planned. The forward-looking statements contained in this press release regarding past trends or activities should not be construed as a statement that such trends or activities will continue in the future. Accordingly, the company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement set forth in this press release as a result of any change in expectations or in events, conditions, assumptions or circumstances. on which these forward-looking statements are based. Neither the company, nor its advisers or representatives, nor any of its subsidiaries, nor any officer or employee guarantees that the assumptions underlying these forward-looking statements are free from error and does not assume any responsibility for the future accuracy forward-looking statements contained in this press release or the actual occurrence of anticipated developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20220920006124/en/